Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders
Frontiers in Nutrition · 12.03.2026 · 13
DOI: 10.3389/fnut.2026.1762061 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 12.03.2026. Verfasst von Xikun Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang University of Chinese Medicine, School of Humanities and Management, Harbin, Heilongjiang, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2022 Project of the Training and Research Center of Ideological and Political Workers in College and Universities of the Ministry of Education, Key Fund Project of Special Research Project in 2023 of the Center for Innovative Development of Ideological and Political Work in Colleges and Universities, Heilongjiang Province Higher Education Teaching Reform Research Key Project.
Abstract (Originalsprache)
Depressive disorder represents a multifaceted and intricate condition characterized by disturbances in monoaminergic signaling, neurotrophic support mechanisms, and the regulation of inflammatory processes. An increasing body of evidence indicates that natural bioactive compounds may provide adjunctive therapeutic advantages with a reduced incidence of adverse effects in comparison to traditional antidepressants. This review investigates the antidepressant efficacy of Rhodiola rosea , Ginkgo biloba , and Ashwagandha, three notable herbal supplements endowed with a variety of neurobiological actions. Rhodiola rosea is known to elevate monoamine concentrations and modulate pathways involved in the stress response, whereas Ginkgo biloba is recognized for its ability to enhance cerebral perfusion, safeguard against oxidative damage, and facilitate synaptic plasticity. Ashwagandha is distinguished by its robust adaptogenic and anti-inflammatory properties, its capacity to diminish cortisol levels, and its role in promoting neurotrophic factors such as brain-derived neurotrophic factor. Collectively, these botanical agents target critical pathways associated with depression, encompassing serotonergic, dopaminergic, and noradrenergic regulation, neurogenesis, mitochondrial functionality, and immunomodulatory processes. Preclinical studies and emerging clinical evidence suggest their potential in alleviating depressive symptoms, fostering resilience, and augmenting overall mental health. This review integrates mechanistic insights and translational findings, highlighting the promise of these natural compounds as adjunctive strategies in depression management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heilongjiang University of Chinese Medicine, School of Humanities and Management, Harbin, Heilongjiang, China.
Förderung
- 2022 Project of the Training and Research Center of Ideological and Political Workers in College and Universities of the Ministry of Education
- Key Fund Project of Special Research Project in 2023 of the Center for Innovative Development of Ideological and Political Work in Colleges and Universities
- Heilongjiang Province Higher Education Teaching Reform Research Key Project
Zitieren
APA
Li, X., Li, X., Li, Y., Liu, Z., Cai, Y., Yao, Q., Zhao, S., & Yu, Q. (2026). Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1762061
Vancouver
Li X, Li X, Li Y, Liu Z, Cai Y, Yao Q, et al. Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1762061
BibTeX
@article{Li2026,
author = {Li, Xikun and Li, Xuyi and Li, Yunchu and Liu, Zhishuo and Cai, Yihan and Yao, Qinqin and Zhao, Shuang and Yu, Qinming},
title = {Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1762061}
}
EUVIMED